ASCO 2024 | Final results of avelumab and axitinib in RCC in the JAVELIN Renal 101 trial
Camillo Porta, MD, University of Bari Aldo Moro, Bari, Italy, comments on the final analysis of the JAVELIN Renal 101 trial (NCT02684006), which compared avelumab and axitinib to sunitinib as first-line treatment for advanced renal cell carcinoma (aRCC). The study reports longer progression-free survival (PFS) with avelumab and axitinib, especially in patients with PD-L1-positive tumors, and a higher objective response rate (ORR) in the overall population. Though overall survival (OS) favored avelumab and axitinib, it did not reach statistical significance. Avelumab and axitinib is therefore, not recommended as standard practice. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consulting or Advisory Role – AstraZeneca; Bristol-Myers Squibb; Eisai; Exelixis; Genenta Science; Ipsen; Merck Serono; MSD
Speakers’ Bureau – Bristol-Myers Squibb; Eisai; Ipsen; Lilly; MSD; MSD
Travel, Accommodations, Expenses – Ipsen; MSD
